Daniel H. Palmer
0000-0002-5766-9990
Publication & Citation Trends
Publications
412 total
Improving long-term outcomes in resectable pancreatic cancer
Cited by 0
Semantic Scholar
Reply to: Adjuvant Treatment Options and Modalities in Pancreatic Adenocarcinoma: Insights From ESPAC4.
Cited by 1
Semantic Scholar
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer.
Cited by 1
Semantic Scholar
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial PDF
Cited by 730
OpenAlex
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study PDF
Cited by 1,197
OpenAlex
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Cited by 2,503
OpenAlex
Therapeutic developments in pancreatic cancer: current and future perspectives
Cited by 1,218
OpenAlex
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial PDF
Cited by 1,903
OpenAlex
Research Topics
Pancreatic and Hepatic Oncology Research
(130)
Hepatocellular Carcinoma Treatment and Prognosis
(103)
Cholangiocarcinoma and Gallbladder Cancer Studies
(59)
Cancer Genomics and Diagnostics
(52)
Cancer Immunotherapy and Biomarkers
(42)
Affiliations
Brighton and Sussex Medical School
University of Verona
Texas A&M Health Science Center
University of Minnesota
University Hospitals Birmingham NHS Foundation Trust